GE Healthcare/GlaxoSmithKline team on cancer test improvements; Myriad Genetics reports promising companion Dx results;

> GE Healthcare ($GE) affiliate Clarient Diagnostic Services will work with GlaxoSmithKline ($GSK) to develop better laboratory and data analytics testing for cancer. Release

> Myriad Genetics ($MYGN) said its BRACAnalysis CDx companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations in 44% of women with ovarian cancer. Release

> A European regulatory committee is recommending marketing authorization for Navidea Biopharmaceuticals' ($NAV) Lymphoseek imaging agent to help diagnose breast cancer, melanoma, or head and neck cancers. Release

> AltheaDx won approval from the New York Department of Public Health for its suite of pharmacogenetic tests and can now sell them across the country. Story (sub. req.)

> Frost & Sullivan gave Roche's ($RHHBY) Ventana Medical Systems a shout-out for having a diverse line of products and services for the cancer diagnostics market. Release

> Foundation Medicine ($FMI), Illumina ($ILMN) and Roche ($RHHBY) are among the companies that participated in the third annual "Blueprint for Drug/Diagnostic Co-development" forum. Item

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.